Cambrex (CBM) Posts Quarterly Earnings Results, Beats Expectations By $0.17 EPS

Cambrex (NYSE:CBM) released its quarterly earnings data on Thursday. The biotechnology company reported $1.27 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.17, Bloomberg Earnings reports. The firm had revenue of $182.28 million during the quarter, compared to the consensus estimate of $181.39 million. Cambrex had a return on equity of 23.42% and a net margin of 18.79%. The firm’s quarterly revenue was up 2.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.23 earnings per share. Cambrex updated its FY18 guidance to $2.80-3.03 EPS.

Shares of Cambrex (NYSE:CBM) traded down $2.30 during trading on Thursday, reaching $50.70. 1,111,257 shares of the company’s stock were exchanged, compared to its average volume of 352,136. The company has a market capitalization of $1,730.00, a P/E ratio of 16.33, a PEG ratio of 1.24 and a beta of 2.38. Cambrex has a fifty-two week low of $42.55 and a fifty-two week high of $62.95.

A number of institutional investors have recently made changes to their positions in CBM. Advisor Group Inc. raised its holdings in Cambrex by 29.8% in the second quarter. Advisor Group Inc. now owns 2,681 shares of the biotechnology company’s stock worth $160,000 after purchasing an additional 615 shares in the last quarter. Visionary Asset Management Inc. bought a new position in Cambrex in the third quarter worth about $201,000. Trexquant Investment LP bought a new position in Cambrex in the third quarter worth about $209,000. Flinton Capital Management LLC raised its holdings in Cambrex by 90.9% in the second quarter. Flinton Capital Management LLC now owns 3,570 shares of the biotechnology company’s stock worth $213,000 after purchasing an additional 1,700 shares in the last quarter. Finally, Sei Investments Co. raised its holdings in Cambrex by 3,120.9% in the third quarter. Sei Investments Co. now owns 4,155 shares of the biotechnology company’s stock worth $228,000 after purchasing an additional 4,026 shares in the last quarter.

CBM has been the subject of several recent research reports. William Blair initiated coverage on Cambrex in a report on Tuesday, January 16th. They issued an “outperform” rating for the company. Craig Hallum restated a “buy” rating and issued a $60.00 price objective (down from $70.00) on shares of Cambrex in a report on Tuesday, October 31st. Finally, Zacks Investment Research upgraded Cambrex from a “strong sell” rating to a “hold” rating in a report on Monday, January 15th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. Cambrex has an average rating of “Hold” and a consensus target price of $60.00.

TRADEMARK VIOLATION WARNING: “Cambrex (CBM) Posts Quarterly Earnings Results, Beats Expectations By $0.17 EPS” was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/02/08/cambrex-cbm-issues-quarterly-earnings-results.html.

About Cambrex

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Earnings History for Cambrex (NYSE:CBM)

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply